Literature DB >> 1656807

Changes of copper level and cytochrome c oxidase activity in the macular mouse with age.

Y Meguro1, H Kodama, T Abe, S Kobayashi, Y Kodama, M Nishimura.   

Abstract

The macular mouse is an animal model of Menkes disease. The neurological degeneration is caused by decreased cuproenzymes activity, such as cytochrome c oxidase (CCO), associated with copper deficiency in the brain. We investigated the age-related changes in copper concentration and CCO activity in the brain of macular mice which were given a single injection of cupric on postnatal day 7. The copper concentration in the brain of macular mice was always about 40% of that of the age-matched controls. However, the copper concentration of both macular and control mice increased with age gradually. The CCO activity in the brain of macular mice was significantly lower than that of controls at the age of 8 days. However the activity in macular mice increased with growth and reached a level equal to the controls at 180 days. These results suggest that the improvement of CCO activity in the brain of macular mice is due to the brain copper concentration which increased with age. Therefore, parenteral administration of copper is recommended especially during infancy in patients with Menkes disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1656807     DOI: 10.1016/s0387-7604(12)80027-1

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  7 in total

Review 1.  ATP7A-related copper transport diseases-emerging concepts and future trends.

Authors:  Stephen G Kaler
Journal:  Nat Rev Neurol       Date:  2011-01       Impact factor: 42.937

Review 2.  Molecular basis of neurodegeneration and neurodevelopmental defects in Menkes disease.

Authors:  Stephanie Zlatic; Heather Skye Comstra; Avanti Gokhale; Michael J Petris; Victor Faundez
Journal:  Neurobiol Dis       Date:  2015-01-10       Impact factor: 5.996

3.  Electron microscopic study of retinas of macular mice.

Authors:  K Mishima; Y Dake; T Amemiya; M Nishimura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-08       Impact factor: 3.117

4.  Pharmacological activity of metal binding agents that alter copper bioavailability.

Authors:  Marian E Helsel; Katherine J Franz
Journal:  Dalton Trans       Date:  2015-05-21       Impact factor: 4.390

Review 5.  Recent developments in Menkes disease.

Authors:  H Kodama
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

6.  Similar splicing mutations of the Menkes/mottled copper-transporting ATPase gene in occipital horn syndrome and the blotchy mouse.

Authors:  S Das; B Levinson; C Vulpe; S Whitney; J Gitschier; S Packman
Journal:  Am J Hum Genet       Date:  1995-03       Impact factor: 11.025

7.  Effect of copper and diethyldithiocarbamate combination therapy on the macular mouse, an animal model of Menkes disease.

Authors:  H Kodama; E Sato; Y-H Gu; K Shiga; C Fujisawa; T Kozuma
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.750

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.